Form 8-K NEUROCRINE BIOSCIENCES For: Apr 15
Tweet
Share
E-mail Exhibit 3.1
BYLAW AMENDMENT
3.2 NUMBER OF DIRECTORS
The board of directors shall consist of nine (9) members. The number of directors may be changed by an amendment to this bylaw, duly adopted by the board of directors or by the stockholders, or by a duly adopted amendment to the certificate of incorporation. The directors shall be divided into three classes, with the term of office of the first class (Class I Directors), which class shall initially consist of three (3) directors, to expire at the 2021 annual meeting of stockholders; the term of office of the second class (Class II Directors), which class shall initially consist of three (3) directors, to expire at the 2022 annual meeting of stockholders; the term of office of the third class (Class III Directors), which class shall initially consist of three (3) directors, to expire at the 2023 annual meeting of stockholders; and thereafter for each such term to expire at each third succeeding annual meeting of stockholders held after such election.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neurocrine Biosciences (NBIX) and Sentia Medical Sciences Extend Research Collaboration to Discover Novel CRF Peptides
- Stemtech Corporation on Track for CEO and Chairman's Goal for Growth and Global Expansion
- Cybeats to Attend RSA Cybersecurity Conference in San Francisco
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
